Shares Magazine
1,957.00p-8.00 (-0.41%)27 Nov 2024, 16:35
Jump to:
Hikma Pharmaceuticals PLC Fundamentals
| Company Name | Hikma Pharmaceuticals PLC | Last Updated | 2024-11-27 |
|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Sector | Healthcare |
| Shares in Issue | 221.885 m | Market Cap | £4.34 bn |
| PE Ratio | 28.97 | Dividend per Share | $0.62 |
| Dividend Yield | 3.13 | Dividend Cover | 1.37 |
| EPS | $0.85 | EPS Growth (%) | 0.23 |
| PEG | 0 | DPS Growth (%) | 0.1711 |
| Debt Ratio | 0.2545 | Debt Equity Ratio | 0.4686 |
| Asset Equity Ratio | 2.1186 | Cash Equity Ratio | 0.1037 |
| Quick Ratio | 0.7603 | Current Ratio | 1.57 |
| Price To Book Value | 2.4839 | ROCE | 0 |
Hikma Pharmaceuticals PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|---|---|---|---|---|
| Interim | 2024-08-15 | 2024-09-20 | USD | 0.3200 | |
| Prelim | 2024-03-21 | 2024-05-03 | USD | 0.4700 | |
| Interim | 2023-08-10 | 2023-09-15 | GBP | 0.1988 | |
| Prelim | 2023-03-23 | 2023-05-05 | GBP | 0.2952 | |
| Interim | 2022-08-18 | 2022-09-20 | GBP | 0.1600 | |
| Prelim | 2022-03-17 | 2022-04-28 | GBP | 0.2600 |
Hikma Pharmaceuticals PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | $1.14 bn | $1.08 bn | $1.15 bn |
| Intangible Assets | $1.10 bn | $1.12 bn | $892.00 m |
| Investments | $83.00 m | $75.00 m | $46.00 m |
| Total Fixed Assets | $2.58 bn | $2.47 bn | $2.28 bn |
| Stocks | $891.00 m | $776.00 m | $695.00 m |
| Debtors | $789.00 m | $777.00 m | $784.00 m |
| Cash & Equivalents | $229.00 m | $292.00 m | $450.00 m |
| Other Assets | $256.00 m | $192.00 m | $194.00 m |
| Total Assets | $4.68 bn | $4.47 bn | $4.37 bn |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | $1.34 bn | $1.08 bn | $1.02 bn |
| Creditors after 1 year | $1.13 bn | $1.25 bn | $889.00 m |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | $2.47 bn | $2.32 bn | $1.91 bn |
| Net assets | $2.21 bn | $2.15 bn | $2.47 bn |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | $40.00 m | $40.00 m | $42.00 m |
| Share Premium | $282.00 m | $282.00 m | $282.00 m |
| Profit / Loss | $281.00 m | $233.00 m | $544.00 m |
| Other Equity | $2.20 bn | $2.13 bn | $2.45 bn |
| Preference & Minorities | $11.00 m | $13.00 m | $14.00 m |
| Total Capital Employed | $2.21 bn | $2.15 bn | $2.47 bn |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | $0.32 | $0.35 | $0.23 |
| Debt-to-Equity | $0.47 | $0.53 | $0.30 |
| Assets / Equity | 2.1186 | 2.1186 | 2.1186 |
| Cash / Equity | 0.1037 | 0.1037 | 0.1037 |
| EPS | $1.70 | $1.39 | $1.75 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | $737.00 m | $585.00 m | $638.00 m |
| Cashflow before financing | $400.00 m | $527.00 m | $351.00 m |
| Increase in Cash | -$62.00 m | -$135.00 m | $113.00 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | $2.88 bn | $2.52 bn | $2.55 bn |
| Cost of sales | $1.49 bn | $1.28 bn | $1.25 bn |
| Gross Profit | $1.39 bn | $1.24 bn | $1.30 bn |
| Operating Profit | $367.00 m | $282.00 m | $582.00 m |
| Pre-Tax profit | $281.00 m | $233.00 m | $544.00 m |
Hikma Pharmaceuticals PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world. |
| Latest Interim Date | 8 Aug 2024 |
| Latest Fiscal Year End Date | 22 Feb 2024 |
Hikma Pharmaceuticals PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2023-03-16 | Dr. Pamela Josephine Kirby | Non-Executive Director |
| 2024-04-11 | Mr. Mazen Samih Taleb Darwazah | Executive Director,Vice Chairman |
| 2014-05-15 | Sir David Kenneth Rowe-Ham GBE | Non-Executive Director |
| 2017-05-19 | Mr. Michael Richard Dwyer Ashton | Non-Executive Director |
| 2014-05-15 | Mr. Samih Darwazah | Non-Executive Director,Chairman |
| 2024-03-22 | Mr. Mohammed Ali Khaldoun S Al-Husry | Non-Executive Director |
| 2016-05-12 | Mr. Breffni Byrne | Non-Executive Director |
| 2024-03-22 | Mr. Douglas Michael Hurt | Non-Executive Director |
| 2018-05-18 | Dr. Ronald L Goode | Non-Executive Director |
| 2024-06-05 | Mr. Said Darwazah | Executive Director,Chairman |
| 2022-05-24 | Mr. Sigurdur O. Olafsson | Executive Director,Chief Executive Officer |
| 2021-03-17 | Mr. Robert Pickering | Non-Executive Director |
| 2024-03-22 | Ms. Nina Henderson | Non-Executive Director |
| 2024-03-22 | Mr. Patrick Butler | Non-Executive Director |
| 2024-03-22 | Mr. John Julius Castellani | Non-Executive Director |
| 2024-03-22 | Ms. Cynthia L. Flowers | Non-Executive Director |
| 2024-03-22 | Dr. Deneen Vojta | Non-Executive Director |
| 2024-09-24 | Mr. Riad Mishlawi | Executive Director,Chief Executive Officer |
Hikma Pharmaceuticals PLC Contact Details
| Company Name | Hikma Pharmaceuticals PLC |
|---|---|
| Address | 1 New Burlington Place, London, W1S 2HR |
| Telephone | +44 2073992760 |
| Website | https://www.hikma.com |
Hikma Pharmaceuticals PLC Advisors
| Auditor | PricewaterhouseCoopers LLP |
|---|---|
| Phone | +44 2075835000 |
| Fax | +44 2078224652 |
| Remuneration Consultant | Willis Towers Watson |
|---|---|
| Phone | +44 2071702000 |
| Fax | +44 2071702222 |
| Solicitor | Slaughter and May |
|---|---|
| Phone | +44 2076001200 |
| Fax | +44 2070905000 |
| Registrar | Capita Asset Services |
|---|---|
| Phone | +44 8716640300 |
| Fax | +44 2086392342 |
| Stockbroker | Bank of America Merrill Lynch |
|---|---|
| Phone | +44 2076281000 |
| Fax | +44 2078672867 |
| Solicitor | Addleshaw Goddard LLP |
|---|---|
| Phone | (020) 7606 8855 |
| Fax | (020) 7606 4390 |
| Financial PR Adviser | FTI Consulting Inc |
|---|---|
| Phone | +44 2037271000 |
| Fax | +44 2037271007 |
| Stockbroker | Citi |
|---|---|
| Phone | +44 2079864000 |
| Fax | +44 2079862266 |
Most Read
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
